SNY vs XNCR: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
SNY is the larger of the two ($103.23B market cap): the incumbent the market prices for continued execution (8.34x forward earnings, beta 0.28). XNCR is the smaller challenger ($2.16B), priced similarly on forward earnings (-8.31x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
SNY vs XNCR: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | SNY | XNCR | What it tells you |
|---|---|---|---|
| Market cap | $103.23B | $2.16B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.34 | -8.31 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.28 | 0.84 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 19% of range | 98% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how SNY and XNCR affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SNY and XNCR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SNY and XNCR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Sanofi (SNY) do?
Sanofi S.A. is one of the world's largest pharmaceutical companies, based in France and organized around biopharma (specialty care, general medicines) and vaccines. Its single most important product is Dupixent, an immunology drug co-developed with Regeneron that treats conditions like eczema, asthma, and COPD; Dupixent sales moved above the roughly four-billion-euro-per-quarter mark in Q1 2026 and grew more than 30% year over year, making it the engine of the company's revenue growth. Sanofi also runs a major vaccines business (including the RSV antibody Beyfortus and the newly acquired hepatitis-B vaccine Heplisav-B) and spun off its consumer-health arm, Opella (Allegra, Icy Hot, Dulcolax), in 2025 to focus purely on innovative medicines and vaccines.
What does Xencor (XNCR) do?
Xencor, Inc. engineers antibodies. Its XmAb platform makes small, deliberate changes to an antibody's Fc region and binding domains, altering how long the molecule persists in the body, how strongly it recruits immune cells, or whether it can grip two targets at once. The company licenses those engineered domains to larger drugmakers and runs its own pipeline from Pasadena, California. Partnered products already carry the technology into approved medicines, with royalties arriving from Alexion on Ultomiris and from Incyte on tafasitamab, and Zenas BioPharma filed a US application for obexelimab in IgG4-related disease in May 2026 that triggered a ~$10 million milestone to Xencor in June.
SNY vs XNCR: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- SNY drivers: Dupixent as the growth engine; Pipeline and new launches.
- XNCR drivers: The TL1A franchise carries the equity story; Royalties and milestones offset part of the burn.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it. For XNCR, every meaningful catalyst here is binary.
SNY or XNCR: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick SNY if you believe its drivers more; XNCR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SNY and XNCR guides.
SNY vs XNCR: the full fundamentals
SNY. Figures are approximate, drawn from public 2026 reporting, and tied to the asOf date; verify live numbers before acting. Sanofi reports in euros, so the dollar value of SNY and its dividend also depends on the euro-to-dollar exchange rate. As a defensive large-cap pharma, the stock tends to trade on pipeline news, Dupixent momentum, and the eventual patent-expiry timeline rather than on sharp cyclical swings.
XNCR. Conventional multiples do not describe this business well. Backing out roughly ~$486 million of cash leaves an enterprise value near ~$1.7 billion against trailing revenue of about ~$105 million, and that revenue is partly one-off settlement and milestone money rather than a repeatable run rate. Earnings multiples do not apply at all while the company loses money by design, so the practical comparison is enterprise value against the addressable market the TL1A programs would reach if they work.
Headline figures (approximate, Jul 2026): SNY shows company type Large-cap, diversified global pharmaceutical company (French, US-listed as an ADR on Nasdaq), market cap ~$107 billion (approximate; among the larger global pharma names), q1 2026 revenue ~10.5 billion euros, ahead of consensus (reported figures are in euros), q1 2026 business eps ~1.88 euros, up ~14% at constant exchange rates; XNCR shows revenue (ttm) ~$105 million, revenue (q2 2026) ~$51.2 million, up from ~$43.6 million a year earlier, r&d expense (q2 2026) ~$71.9 million, net loss (first half 2026) ~$150.6 million, or ~$1.99 per share.
The bottom line: SNY vs XNCR
SNY and XNCR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined SNY and XNCR exposure against your real portfolio. It is not an investment adviser.
Wondering how SNY or XNCR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Sanofi with AI
Connect the broker you already use and ask Walnut's AI how SNY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between SNY and XNCR?
+
Sanofi S.A. Xencor, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is SNY or XNCR the better stock?
+
Neither is universally better. SNY is the larger incumbent; XNCR is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, SNY or XNCR?
+
On forward P/E (as of August 2026), SNY trades at 8.34x and XNCR at -8.31x, so XNCR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both SNY and XNCR?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of SNY vs XNCR?
+
SNY: The clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it. Drug development is inherently uncertain, as the December 2025 US complete response letter for tolebrutinib in non-relapsing secondary progressive MS showed, even as the EU approved it. Because SNY is an ADR of a euro-reporting company, currency swings between the euro and dollar affect reported results and the dollar value of the dividend, adding volatility unrelated to the business. Pharma also faces pricing pressure, US drug-pricing policy, patent litigation, and competition from large rivals and biosimilars. Vaccine demand is seasonal and competitive, as Beyfortus experienced in the US market. XNCR: Every meaningful catalyst here is binary. A disappointing blinded interim on XmAb942, or induction data in 2027 that fails to separate from what Merck has already shown with tulisokibart, would remove the reason most of the current market capitalisation exists. The TL1A field is crowded with far better-funded rivals, including Merck, which paid $10.8 billion for Prometheus to acquire the lead asset, plus Roche, Sanofi with Teva, and AbbVie with FutureGen, so being second or third to market with a similar mechanism is a real commercial outcome. Cash guidance of through-2028 assumes the current plan holds, and a broadened Phase 3 program or a slower partnering environment could force dilution at whatever price the stock happens to be. Losing the US Ultomiris royalty stream permanently narrows the non-dilutive funding base just as spending rises.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell SNY or XNCR; figures are approximate and dated (as of August 2026). Verify current data before investing.